Mr. Aldrich is participating in the "Executive Leadership Panel: Generating the Future in the Skin Anti-Aging Category," on Tuesday, June 28, at 1:30 p.m. Dr. Semechkin is presenting at the Expo's Anti-Aging Symposium as an expert on emerging technologies in skincare. Dr. Semechkin's presentation, titled "Stem Cell Derived Growth Factors - the Next Breakthrough in Anti-Aging," is scheduled for Wednesday, June 29, at 1:30 p.m.
International Stem Cell is a world leader in the research and development of parthenogenetic stem cells for therapeutic applications and is developing and commercializing stem cell-based research and cosmetic products through Lifeline Skin Care®. The first cosmetic products, a defensive day moisture serum and a recovery night moisture serum containing extracts from human parthenogenetic stem cells, were launched in November 2010 and are available for purchase through www.lifelineskincare.com and selected luxury spas across the United States.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?
Statements pertaining to anticipated developments, product development and marketing plans, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, competition, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
Ruslan Semechkin, PhD
Vice President, ISCO
President and CEO, Lifeline Skin Care
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
Post a Comment